Century Therapeutics, Inc. (IPSC) vs SAB Biotherapeutics, Inc. (SABS)

Century Therapeutics, Inc. and SAB Biotherapeutics, Inc. are both Biotechnology companies. Century Therapeutics, Inc. and SAB Biotherapeutics, Inc. are of similar size ($306.0M and $304.8M). Century Therapeutics, Inc. grew revenue faster over the last twelve months: 8,286.7% against −60.3%. Across the 14 metrics below, SAB Biotherapeutics, Inc. leads on 8 and Century Therapeutics, Inc. on 6.

Valuation

Metric IPSC SABS Biotechnology median
P/E n/m n/m 7.88
P/S 2.99 161.23 11.47
P/B 1.48 1.22 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 1.95 100.03 10.73
Earnings yield (55.69%) (19.45%) (28.84%)
Free cash flow yield (25.62%) (21.89%) (23.03%)

Profitability

Metric IPSC SABS Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (49.65%) (19.21%) (57.72%)
Return on assets (38.41%) (16.24%) (49.22%)
Return on invested capital (64.92%) (38.97%) 0.00%

Growth

Metric IPSC SABS Biotechnology median
Revenue growth (TTM) 8,286.72% (60.26%) 5.64%
EPS growth (last fiscal year) 93.12% 78.53% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% (26.69%) 0.00%

Health

Metric IPSC SABS Biotechnology median
Debt to equity 0.00 0.01 0.00
Current ratio 8.28 9.22 4.73
Net debt to EBITDA 17.95 2.03 0.96

Dividend

Metric IPSC SABS Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric IPSC SABS Biotechnology median
Market cap 306.02m 304.80m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack